Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

BioSynthema Inc
Profile last edited on: 11/19/07      CAGE: 3PTH3      UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
2001
First Award
2003
Latest Award
2003
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

4041 Forest Park Avenue
St. Louis, MO 63108
   (314) 615-6365
   jlerion@biosynthema.com
   www.biosynthema.com
Location: Single
Congr. District: 01
County: St. Louis city

Public Profile

BioSynthema Inc. discovers, develops and commercializes diagnostic and therapeutic product pairs that can lead to the early detection, monitoring, and treatment of cancer. BioSynthema's technology utilizes novel receptor-targeted peptides to develop radiopharmaceuticals for the diagnosis and treatment of cancer

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$100,000
Phase II Dollars
$0
Total Awarded
$100,000

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2003 1 NIH $100,000
Project Title: Receptor Targeted, RGD-Linked, Cytotoxic Peptides

Key People / Management

  Jack L Erion -- President

Company News

There are no news available.